Stocks to watch next week: Broadcom, Lululemon, British American Tobacco, Dr Martens and Rémy Cointreau
Tariffs remain in focus as earnings season continues to wind down, but there are still a number of key companies due to report in the coming week.
On the back of a strong set of results from chipmaking giant Nvidia (NVDA), attention will now turn to rival Broadcom (AVGO), which is due to report on Thursday.
Athletics wear company Lululemon (LULU) is also due to report on Thursday, with focus on its outlook for the current year, after guidance offered at the end of the last financial year failed to impress investors.
In London, investors will want to see if British American Tobacco (BATS.L) has continued to generate sales growth from its new categories business, which includes vapes and heated products.
Investors will also be keen to see how Dr Martens (DOCS.L) turnaround efforts are progressing when the iconic bootmaker reports its full-year results on Thursday.
On the Paris bourse, Rémy Cointreau's (RCO.PA) full-year performance will be in focus, ahead of a new CEO taking the helm at the French spirits company later in June.
Here's more on what to look out for:
Shares in Nvidia (NVDA) jumped after it reported another blowout quarter on Wednesday, despite the company warning of the impact of export controls that limit its ability to ship products to China.
The chipmaker posted revenue of $44.1bn (£32.7bn) for the first quarter, beating expectations of $43.3bn, though earnings per share of $0.81 came in below estimates of $0.93.
Derren Nathan, head of equity analysis at Hargreaves Lansdown, said: "The first key takeaway from Nvidia's (NVDA) Q1 print was that demand for accelerated computing remains extremely strong due to the lightning speed roll out of AI. The second is that Nvidia remains the dominant force in this market."
"However, with McKinsey predicting a spend of around $7tn to help data centres keep pace with processing demands out to 2030, the market is big enough to accommodate more than just one player," he added. "Broadcom's (AVGO) custom ASIC chips can help hyperscalers lower their average cost of data processing and as such it looks well set to grow its share of the market."
Read more: What's behind the surge in AI-related lawsuits?
Nathan said that consensus forecasts for Broadcom's (AVGO) second quarter revenue are broadly in line with the company's guidance of approximately $14.9bn, which works out to growth of around 19%.
He highlighted that artificial intelligence (AI) is a "growing share of Broadcom's (AVGO) revenue base but there's still more sales coming from non-AI workloads leaving the company exposed to cyclical ups and downs, which is a risk in today's macroeconomic environment. And with 20% of revenue coming from China, markets will be keen to hear the potential impact of export restrictions and tariffs."
Nathan added that estimates for Broadcom's (AVGO) third quarter revenue have been falling slightly over the last month and currently stand at $15.8bn. "But with so many moving parts to the picture the company's steer will be a key metric to focus on," he said.
Broadcom (AVGO) shares popped after the company posted first quarter results in March that beat on the top and bottom lines, driven by AI chip sales. Adjusted net revenue came in at $14.92bn, versus expectations of $14.61bn, while adjusted earnings per share of $1.60 were ahead of estimates of $1.50. However, fluctuations in the stock since then have left it up just 4.4% year-to-date.
Shares in Lululemon (LULU) sunk after its earnings outlook appeared to underwhelm investors, despite the company posting better-than-expected quarterly profits in March.
The athletics wear retailer said it expected earnings per share for this year to be in the range of $14.95 to $15.15, which was below expectations of $15.37. On revenue, the company said it expected this to be in the range of $11.15bn to $11.3bn.
In addition, Lululemon (LULU) chief financial officer (CFO) told investors on an earnings call that the company was not expecting store traffic to improve this year versus softness out of the gate in the first quarter.
Read more: Stocks that are trending today
In a note on 12 May, Barclays analysts – which had an "equal weight" rating on Lululemon (LULU) – said they were "cautious" on the stock.
They highlighted that the retailer's "We Made Too Much" online clearance section "showed an increase towards the end of the quarter".
"During 1Q25, the WMTM category negatively inflected in the final few weeks of the quarter," they said.
They said this suggested "potential for weaker exiting trends and building inventory risk".
For the first quarter, Lululemon (LULU) said it expected net revenue to come in between $2.34bn and $2.36bn, which would represent growth of 6% to 7%. Diluted earnings per share are expected to be in the range of $2.53 to $2.58 for the quarter.
On Wednesday, British American Tobacco (BATS.L) announced that it had sold a 2.5% stake in Indian consumer goods company ITC (ITC.NS), which was worth $1.5bn, according to a Reuters report.
The company said that the transaction would give it "greater financial flexibility as it delivers on its commitment to invest behind transformation, deleverage and enhance shareholder returns."
The tobacco giant also said that the net proceeds from the trade would be used to extend its existing share buyback programme by an additional £200m ($269.5m), taking the total amount it repurchases in 2025 to £1.1bn.
That was up on £900m BAT (BATS.L) said it planned to undertake in buybacks this year back in its preliminary results release in February.
Shares tumbled after the release of those results, in which the company flagged £6.2bn ($7.7bn) hit, from a proposed settlement of a long-running lawsuit in Canada. With this provision, the company posted reported profit from operations for the year of £2.74bn.
Read more: Government 'megafund' pension plans could give £6k boost to savers
BAT (BATS.L) posted a 5.2% decline in reported revenue for the year at £25.9bn, driven by the sale of its businesses in Russia and Belarus in September 2023 and transnational foreign exchange headwinds. However, the company saw 8.9% organic growth from revenue in its new categories business at £3.4bn.
Nathan, of Hargreaves Lansdown, said that the company "heads into its upcoming [first-half] trading update with investor attention firmly on its ability to navigate persistent industry headwinds".
"Regulatory pressures and rising tobacco taxes continue to weigh on the outlook," he said.
"As such, this year's guidance for around 1% sales growth and 1.5–2.5% profit growth currently stands below the group's medium-term targets. The upcoming update will be closely watched for signs that 'new categories' can deliver more meaningful growth and help offset the structural decline in traditional tobacco."
In addition, Nathan said that investors "will be watching closely to see if US action to crackdown on illegal competition has had any impact and whether the lifting of a proposed ban on menthol cigarettes has helped the outlook".
According to consensus forecasts provided by the company on its website, analysts expect full-year total revenue for 2025 to come in at £26.2bn, including £3.88bn from new category business.
Shortly after taking over as Dr Martens (DOCS.L) CEO in January, Ije Nwokorie said in a third quarter trading update that the bootmaker had made "good progress" on turning round performance in the US.
He said that the team were focused on "returning the business to sustainable and profitable growth".
In the third quarter, Dr Martens (DOCS.L) reported 3% growth in group revenue at £267m, with a 4% increase in direct-to-consumer business in the Americas.
"Dr Martens (DOCS.L) is expected to deliver more evidence that it is pulling itself up by its bootstraps and the turnaround is lacing together," said Susannah Streeter, head of money and markets at Hargreaves Lansdown. "It's been reducing inventories and debt, preserving cash and stabilising the business overall."
Stocks: Create your watchlist and portfolio
"The iconic footwear company has found it hard going stomping new fashion ground overseas, with the US, its biggest market, proving particularly tough," she said. "But in the key autumn/winter season, there were signs that increased investment in marketing was paying off, with new styles winning fans. It's trying to get the heritage models and new innovations in the fashion market."
Streeter said that the "performance of the last quarter will be a test" for new CEO Nwokorie.
She said that the company's "strategy includes new store roll outs and increasing the direct-to-consumer mix, as well as improving the quality and depth of wholesale distribution.
"It's hoped that the Docs will also take a step forward with the appointment of a new chief brand officer, Carla Murphy, a former Adidas (ADS.DE) global executive who also has experience at VF Corporation, the American global apparel and footwear company."
In its January trading update, company didn't offer specifics on its guidance for the full year but said its outlook remained unchanged and that it was on track to achieve its objectives. Despite signs of turnaround progress, the stock is still down nearly 19% year-to-date.
French cognac maker Rémy Cointreau (RCO.PA) announced on Wednesday that it had appointed Franck Marilly as the company's new CEO, taking over from Eric Vallat, who said last month he would be stepping down.
Marilly, who assumes the role on 25 June, has previously worked for Japanese beauty brand Shiseido (4911.T), luxury fashion house Chanel and consumer goods giant Unilever (ULVR.L).
The news comes as Rémy Cointreau (RCO.PA) navigates challenges around trade tensions with both the US and China, two of its key markets.
In a fourth quarter sales update in April, Rémy Cointreau (RCO.PA) posted an 18% fall in full-year sales at €984.6m (£827.6m). The company flagged a "steep decline" in sales of cognac in China in the fourth quarter, which it said was partly down to "harsh market conditions", among other factors.
Read more: UK 'bargain' stocks that have outperformed the market long-term
In January, China launched an anti-dumping investigation on brandy imported from the European Union (EU), which was extended in April and included the imposing of temporary duties on imports of brandy. The probe was considered to be in response to EU duties on Chinese electric vehicles.
Rémy Cointreau (RCO.PA) said in its April sales update that if the provisional duties were confirmed, the company would "trigger its action plan to mitigate the effects starting in fiscal 2025-26. The impact on fiscal year 2024-25 is marginal."
In addition, there is also uncertainty around US tariffs on the EU, with talks between the two ongoing, after president Donald Trump hit pause on his threat to impose 50% duties on the bloc.
Investors will be looking at Rémy Cointreau's (RCO.PA) final full-year results on Wednesday for any commentary around the potential impact of these tariff challenges in the year ahead.
The company said in April that a €50m (£42m) cost-cutting plan would help protect its operating margin, expecting this to come in between 21% and 22% for the year. It also reiterated its financial targets for 2029-30 of hitting a gross margin of 72% and an operating margin of 33%.
Monday 2 June
Sirius Real Estate (SRE.L)
Campbell's Co (CPB)
Tuesday 3 June
Chemring (CHG.L)
Pennon (PNN.L)
Gooch & Housego (GHH.L)
Crowdstrike Holdings Inc (CRWD)
Ferguson Enterprises Inc (FERG)
Dollar General Corp (DG)
Hewlett Packard Enterprise (HPE)
Nio Inc (NIO)
Signet Jewelers (SIG)
Wednesday 4 June
Paragon Banking (PAG.L)
B&M European Value Retail (BME.L)
DiscoverIE (DSCV.L)
Ramsdens (RFX.L)
Dollar Tree Inc (DLTR)
GameStop (GME)
Thursday 5 June
Mitie (MTO.L)
Workspace (WKP.L)
Young's & Co Brewery (YNGN.L)
Fevertree (FEVR.L)
Fastenal (FAST)
DocuSign (DOCU)
Brown-Forman (BF-B)
Ciena (CIEN)
Wizz Air Holdings (WIZZ.L)
CMC Markets (CMCX.L)
Friday 6 June
ABM Industries Inc (ABM)
Caffyns (CFYN.L)
You can read Yahoo Finance's full calendar here.
Read more:
How getting ahead on your tax return can help cut your tax bill
Odds of more Bank of England interest rate cuts fall as food inflation rises
Trump tariffs to hit UK economy next year, says IMF
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Labour won't be forgiven for failing to tackle immigration
If the 2024 election was in part a rebuke of the Conservative Party's total failure to control migration, 2029 is shaping up to be a far more painful experience for the Labour party. Sir Keir Starmer may have hoped that his immigration white paper, coupled with the fall in net migration triggered by the last policies put in place by the outgoing Tory government, would buy him breathing space until the salience of migration fell again, and he would be freed to talk about other topics. If so, this week should have shredded any such illusions. Both legal and illegal migration are running out of control, with justifiable public anger over the scale of the Government's failure to impose order. More than 1,000 migrants crossed the Channel on Saturday while British and French rescue boats stood by to escort them in. So great was the demand to be transported into Dover that coast guards put out appeals for fishing boats to assist vessels in trouble as Border Force and lifeboats were overwhelmed by the effort of rescuing migrants. Stunning images from France, meanwhile, showed the value of Sir Keir Starmer's much vaunted European cooperation in 'smashing the criminal gangs'. French police were seen simply standing by and watching as migrants loaded their boat for the crossing. The current situation is a travesty in which migrants are encouraged to endanger themselves in order to manufacture a rescue on to British shores, while the French state – which has no greater wish to play host and benefactor to these people than Britain does – does little to stop them. Sir Keir cannot divest himself of blame for this absurdity. His scrapping of the Rwanda deterrent directly removed one of the few ways in which Britain could bring itself to diminish the flow. As a career human rights lawyer and Left-wing activist, the Prime Minister is almost uniquely ill-suited to the task of devising an alternative. He has surrounded himself with like-minded individuals, not least the Attorney General Richard Hermer, and set as his North star the gold-plated adherence to the outdated international rules that allow the vile trade in people to be carried out. If Britain wishes to smash the gangs, it must smash the incentives that bring people here, tackling illegal employment, particularly in the gig economy, radically tightening the criteria for asylum, deporting those whose claims are denied, reducing the grounds for appeal, and ultimately revisiting the idea of a system in which claimants who arrive illegally are transferred to a safe third country. The current illegal migration system suits no one. It enriches dangerous criminals, selects those who have the resources to make the journey to Britain rather than those most imperilled, undermines public safety and support for legal migration, and will, if unchecked, destroy what sympathy for the refugee convention remains. This would be a tragedy. Britain is a country that is open to those who are genuinely in need. It is the task of the Government to make sure that this hospitality, and the taxpayer, are not taken advantage of. Yet even on legal migration – supposedly filtered and controlled – the evidence is that it is manifestly failing to do so. Figures published this week show that the state is handing nearly £1 billion each month in Universal Credit payments to households containing at least one foreign national. While some may have married British nationals, the fact that these payments have doubled over the past three years suggests that something has gone badly wrong at the heart of our benefits system. Despite the apparent beliefs of many in Westminster, Britain is not the world's welfare state. Moreover, the rationale for migration is not that it is good for the migrant, but that it is good for Britain. The people of this country accept willingly new members who pay their way, contribute, and work to assimilate into our find ourselves instead asked to pay for the upkeep of those who arrived on our shores courtesy of a system that was supposed to provide economic and fiscal strength is an illustration of utter failure. Just as measures must be taken to control illegal migration, the flow of low-skilled, low prospect migrants into Britain must also be curtailed. The criteria for entry should be considerably tightened, eligibility for benefits confined to those with citizenship, and pathways to both that status and indefinite leave to remain tightened considerably, with rules put in place to ensure that only those who make a positive fiscal contribution qualify. The legitimacy of the British state is based on the consent of the governed to the rule of their elected representatives. After 15 years of votes to lower migration, and 15 years of broken promises, patience is beginning to wear thin, with surging support for Reform UK emblematic of an increasing rejection of the current political establishment. Unless Sir Keir can find the iron within himself to crack down on both legal and illegal migration, he is unlikely to be granted a second term in Downing Street. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
3 hours ago
- Yahoo
TSMC Stock Maintains High-Conviction AI Play Status With $220 Price Target
Taiwan Semiconductor Manufacturing Company (TSM), or TSMC for short, the world's numero uno pure-play semiconductor foundry, has surged nearly 20% over the past month. Despite this impressive rally, my outlook remains bullish. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The company is well-positioned to benefit from powerful tailwinds, including relentless AI-driven demand, a dominant—nearly monopolistic—position in advanced chip manufacturing, ongoing geographic diversification, and a steady cadence of technological breakthroughs. TSMC continues to be the principal manufacturer and primary supplier of chips for leading AI powerhouses, including Nvidia (NVDA), Advanced Micro Devices (AMD), Apple (AAPL), and Qualcomm (QCOM). Notably, TSM is also the producer of Nvidia's cutting-edge Blackwell chip series, which has recently gained immense popularity. TSMC's 3nm process currently represents the most advanced semiconductor technology in the industry, delivering superior power efficiency and performance. Looking ahead, anticipation is building around the company's upcoming 2nm and 1.6nm nodes, scheduled for launch in late 2025 and 2026, respectively. The 2nm technology, referred to as N2, remains on track for volume production in the second half of 2025. This next-generation process is expected to deliver a 10–15% improvement in processing speed at the same power consumption, or a 20–30% reduction in power usage at equivalent performance. Following that, the 1.6nm process is projected to further improve power efficiency by an additional 15–20% over the 2nm node. These advancements are especially timely, as data centers grapple with rising energy costs. The shift to more power-efficient chips is becoming not only a technological imperative but also an economic necessity. This positions TSMC as a key enabler in the ongoing global semiconductor upgrade cycle. Reflecting this momentum, TSMC has outlined strong long-term growth expectations. The company projects its AI-related chip revenue to grow at a compound annual growth rate (CAGR) of 45% over the next five years, while overall revenue is forecast to grow at a 20% CAGR during the same period. These figures underscore the company's pivotal role in powering the future of computing. Such growth potential hasn't gone unnoticed. Famous investor Cathie Wood's Ark funds recently purchased 241,047 shares of Taiwan Semiconductor, worth $46.3 million, signaling firm institutional conviction. TSM commands an overwhelming 64.9% global market share in the foundry segment, dwarfing its closest competitors— Samsung Electronics (SMSN) and Intel (INTC), according to Statista. Its unparalleled scale, deep client relationships, and technological edge create formidable barriers to entry. This dominant position grants TSM significant pricing power. Clients, many of whom have relied on TSM for decades, are unlikely to switch suppliers given the risk of falling behind in the rapidly evolving AI race. One of the major risk factors associated with TSM is its geographical location in Taiwan, which poses the risk of a takeover by China. However, TSM is prioritizing geographic diversification as a core strategic initiative, proactively addressing these risks by diversifying its global manufacturing footprint. In addition to its $65 billion investment in U.S.-based fabs, TSM has committed a further $100 billion to expand capacity globally. Its Arizona facility is reportedly operating at full capacity through 2027, highlighting robust demand. This geographic diversification not only reduces exposure to potential tariffs but also strengthens TSM's resilience to geopolitical volatility. Beyond the U.S., TSM is also establishing a new chip design center in Munich, Germany, as well as a manufacturing plant in Dresden, Germany, and new fabs in Japan. Taiwan Semiconductor's strategic investments beyond its home base reflect prudent risk management and reinforce its strategic shift toward a more balanced global presence. TSM is set to report its Q2 2025 earnings on July 17. The company is projected to report earnings per share (EPS) of $2.30, representing a 57.5% year-over-year increase. Additionally, Q2 revenues are projected to increase by 13% year-over-year, ranging between $28.4 billion and $29.2 billion, driven by high demand for its advanced 3-nanometer (nm) and 5-nm processes. On May 9, TSM unveiled impressive revenue figures for April 2025, marking the highest ever figure in any single month in the company's history. April net revenues galloped 48.1% year-over-year to 349.6 billion New Taiwan dollars (approximately $11.6 billion). It's worth noting that TSM anticipates 24% to 26% sales growth for FY2025, driven by strong demand for its latest nanochips amid the AI surge. Importantly, TSM trades at an attractive valuation compared to its peers. In terms of its valuation, TSM looks cheap. Currently, it's trading at an attractive forward P/E ratio of 21x, compared to much higher multiples of its peer group. Semiconductor company Advanced Micro Devices is trading at a higher forward P/E multiple (28x), while the AI prodigy Nvidia is trading at a forward P/E of 32x. On Wall Street, TSM stock carries a Strong Buy consensus rating based on seven Buy, one Hold, and zero Sell ratings over the past three months. TSM's average stock price target of $219.43 implies approximately 11% upside potential over the next twelve months. The semiconductor industry continues to experience strong growth, driven largely by the rapid adoption of artificial intelligence technologies. TSMC, with its unmatched manufacturing capabilities, deeply embedded customer relationships, and advanced technology roadmap, is exceptionally well-positioned to capitalize on this transformative trend. The company's timely investments in next-generation nodes—specifically 2nm and 1.6nm—alongside its global manufacturing expansion, align well with rising demand fueled by a broad upgrade cycle across the tech landscape. These factors collectively make TSMC a compelling long-term investment opportunity. With a favorable valuation and strong earnings momentum, the current environment presents an attractive entry point for investors looking to gain exposure to the accelerating AI megatrend. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Sanofi (ENXTPA:SAN) Reports Positive Phase 3 Results for Itepekimab in COPD Trial
Sanofi announced that its AERIFY-1 trial with Regeneron Pharmaceuticals successfully met its primary endpoint, indicating progress in COPD treatment. Despite this positive news, the company's share price fell 5% over the last week, contrasting with a 2% rise in the broader market. This decline may reflect investors' reactions to other company initiatives, such as its partnership with Stagecoach Performing Arts to raise awareness of autoimmune Type 1 diabetes. These positive developments, although promising, were not enough to counterbalance the broader market's upward trend, contributing weight against Sanofi's price movement. Buy, Hold or Sell Sanofi? View our complete analysis and fair value estimate and you decide. Uncover the next big thing with financially sound penny stocks that balance risk and reward. The recent successful completion of Sanofi's AERIFY-1 trial could have a positive impact on its revenue and earnings forecasts by strengthening its position in the COPD treatment market. However, despite these promising developments, the company's share price experienced a 5% decline in the past week, contrasting with the broader market's 2% rise. This movement might reflect investor reactions to other company initiatives, such as the partnership with Stagecoach Performing Arts, and broader market trends. Looking at a longer-term context, Sanofi's shares have delivered a total return of 19.59% over the past five years. Recent performance has exceeded the French Pharmaceuticals industry and market, which returned 4% and 4.5% declines respectively over the last year. Such outperformance indicates resilience amidst industry challenges and market volatility. Please consider the current share price of €95.9 against the consensus price target of €117.17, indicating a potential upside potential of approximately 18.5%. This price target is based on expectations of revenue reaching €51.2 billion and earnings of €10.2 billion by 2028, trading on a PE ratio of 16.1x. Analysts are assuming that Sanofi will enhance its growth trajectory driven by its innovative treatments and efficient operational strategies. Assess Sanofi's previous results with our detailed historical performance reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:SAN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
